NCT05524168

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

SBRT Combined With Programmed Death 1 (PD-1) Antibody and Chemotherapy in Nasopharyngeal Carcinoma With Oligometastasis: A Prospective, Multicenter, Single-arm, Phase II Clinical Trial

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 41 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal carcinoma patients with oligometastasis.

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
RADIATION	SBRT	SBRT for metastatic lesions
DRUG	Camrelizumab	Maximum 6 cycles for combined therapy. Camrelizumab maintenance for 1 year.
DRUG	Gemcitabine	Maximum 6 cycles for combined therapy.
DRUG	Cisplatin	Maximum 6 cycles for combined therapy.

Timeline

• Start date: 2022-11-25
• Primary completion: 2025-06-06
• Completion: 2026-12-01
• First posted: 2022-09-01
• Last updated: 2026-01-15

Locations

1 site across 1 country: China